Jonathon Campbell

Building a cost-effective model for tuberculosis screening

Why did you decide to pursue a graduate degree?

I focused primarily on wet lab research as an undergraduate student and early in my career. I personally found the repetitive nature and extensive work required to develop protocols disheartening. When Dr. Fawziah Lalji offered me an innovative project within her lab at UBC Pharm Sci, the chance to shift my career path in the direction of health economics and outcomes research was exciting. We've been moving forward with the project, have crossed the largest hurdles, and the future looks bright.

Why did you decide to study at UBC?

I lived in Toronto my whole life and so when I was presented with the opportunity to complete graduate school outside the province, especially in beautiful British Columbia, I couldn’t say no. I arrived nearly three years ago and have not once regretted my decision. The university and city are incredible.

What do you hope to accomplish with your research?

By identifying the subgroups within these two disease states that benefit the most from screening, we can advise decision makers on where to focus resources to help achieve tuberculosis elimination in BC and across Canada.

What advice do you have for new graduate students?

My advice is to get involved and stay involved. I’ve made the most of my time here by participating as a Pharmaceutical Sciences Graduate Student Society (PharGS) executive, volunteering on various committees, and attending student-organized events. Grad school is much more enjoyable when you’re active and involved. These opportunities will also help to build your CV.


Learn more about Jonathon's research

Tuberculosis in countries such as Canada is largely a result of latent disease reactivation, rather than active case transmission. Tuberculosis screening programs are therefore increasingly geared towards identifying groups with the highest risk for latent disease and subsequent reactivation. My research focuses on screening in diabetics and chronic kidney disease patients - two diseases that are increasing in prevalence at staggering rates and increase the likelihood of tuberculosis reactivation. The crux of my research is building a cost-effectiveness model for latent tuberculosis screening and my main goal (other than accuracy) is to ensure model efficiency.